Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Aging
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Prospective, Double-Blind, Placebo-Controlled TrialMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 50 years and 85 years
- Gender
- Both males and females
Description
A randomized, double-blind, placebo-controlled trial assessing the effects of low, medium, and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, an...
A randomized, double-blind, placebo-controlled trial assessing the effects of low, medium, and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults.
Tracking Information
- NCT #
- NCT04488601
- Collaborators
- University of California, Los Angeles
- Investigators
- Principal Investigator: James Watson, MD University of California, Los Angeles Study Director: Sajad Zalzala, MD AgelessRx
Get Well Soon